These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30381490)

  • 1. Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.
    Van Rompay KKA; Hassounah S; Keele BF; Lifson JD; Ardeshir A; Watanabe J; Pham HT; Chertova E; Sowder R; Balzarini J; Mesplède T; Wainberg MA
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
    J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Del Prete GQ; Smedley J; Macallister R; Jones GS; Li B; Hattersley J; Zheng J; Piatak M; Keele BF; Hesselgesser J; Geleziunas R; Lifson JD
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):163-8. PubMed ID: 26150024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
    Wijting I; Rokx C; Boucher C; van Kampen J; Pas S; de Vries-Sluijs T; Schurink C; Bax H; Derksen M; Andrinopoulou ER; van der Ende M; van Gorp E; Nouwen J; Verbon A; Bierman W; Rijnders B
    Lancet HIV; 2017 Dec; 4(12):e547-e554. PubMed ID: 29107562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
    Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
    Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
    Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.
    Wares M; Hassounah S; Mesplède T; Sandstrom PA; Wainberg MA
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1942-9. PubMed ID: 25583721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
    Yang LL; Li Q; Zhou LB; Chen SQ
    Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.